Hikma Pharmaceuticals USA Inc., et al., Petitioners v. Amarin Pharma, Inc., et al.

The Supreme Court decided a fight over when Amarin's patent suit against Hikma can move forward in a 'skinny label' generic-drug case. The dispute asked whether a generic company can still face induced infringement claims based on calling its product a 'generic version' and citing public sales information, even without label language directing the patented use.

The Court released a decision on June 4, 2026, but the prompt does not provide the vote count or opinion lineup.

Majority

Jackson

Roberts

Thomas

Alito

Sotomayor

Kagan

Gorsuch

Kavanaugh

Barrett

The ruling will shape how generic drug makers talk about their products after carving a patented use out of the FDA label. It also affects how easily brand-name drug companies can keep patent suits alive at the motion-to-dismiss stage.

Lower courts, drug makers, and patent holders will now apply the Court's guidance in similar induced-infringement cases. Any further proceedings in this case will have to follow the Supreme Court's opinion.

The case asked whether a generic drug company can still be sued for inducing patent infringement after leaving a patented use off its label. It also asked whether a complaint can survive without alleging a statement that directly told doctors to use the drug that way.

The decision affects how generic manufacturers describe products in public statements, not just in FDA-approved labels. Brand-name companies also gain clearer rules for when patent claims can proceed past an early dismissal request.

Lower courts must apply the Supreme Court's guidance in this case and similar patent disputes. Drug companies and lawyers will likely adjust labeling and public communications to fit the new rule.